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Abstract
Treatment of multidrug-resistant tuberculosis (MDR-TB), deﬁned as Mycobacterium tuberculosis resistant to both isoniazid and rifampicin, is
challenging under the best of circumstances, and particularly in resource-limited settings. For patients who remain persistently sputum-
culture-positive despite therapy with second-line TB drugs, treatment options are limited, especially if disease is too advanced for resective
surgery. Salvage therapy refers to the design of a regimen combining new and previously used drugs in a ﬁnal effort to attain sputum
conversion before declaring treatment to have failed. We retrospectively evaluated the outcomes of salvage therapy in 213 Peruvian
patients. Salvage regimens included a median of two new drugs (range 1–6) and nine (range 5–13) total (new plus previously used) drugs.
The most frequently used new drug was moxiﬂoxacin, followed by capreomycin, amoxicillin-clavulanate, kanamycin and clarithromycin.
Culture conversion occurred in 65 (30.5%) patients. Salvage regimens that included moxiﬂoxacin were signiﬁcantly more likely to be
followed by culture conversion (OR 2.2; p 0.02). Later-generation ﬂuoroquinolones such as moxiﬂoxacin should be used in salvage therapy
but also in the initial treatment of MDR-TB, if the best clinical strategy is to use the most effective drugs when the patient has the best
chance for cure. New TB drugs are most likely to be initially used in salvage patients, in conditions similar to those described here. Close
bacteriological monitoring of these patients will be essential, as useful information about the best way to use these new drugs can be gained
from analysis of salvage therapy cohorts.
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Introduction
Treatment of multidrug-resistant tuberculosis (MDR-TB),
deﬁned as Mycobacterium tuberculosis resistant to both isoniazid
and rifampicin, is challenging under the best of circumstances,
and particularly in resource-limited settings. Even with a well-
designed regimen [1–3], excellent adherence, and good
adverse event management [4–6], MDR-TB treatment can be
expected to fail to achieve durable culture conversion in a
certain proportion of patients [7]. Most MDR-TB patients who
eventually go on to cure have sputum cultures that convert
from positive to negative by the 6th month of treatment [5,8].
For patients who remain persistently sputum-culture-positive
despite therapy with second-line TB drugs, treatment options
are limited, especially if disease is too advanced for resective
surgery. In these patients, salvage therapy refers to the design
of a regimen combining new and previously used drugs in a
ﬁnal effort to attain sputum conversion before declaring
treatment to have failed.
Since 1996, the Peru National TB Programme has been
diagnosing and treating thousands of MDR-TB patients using an
innovative model of community-based care [5,9]. Within this
large number of closely monitored, highly adherent MDR-TB
patients, we identiﬁed a cohort of persistently positive patients
who received salvage therapy. We evaluated the outcome of
salvage therapy in these patients and compared the frequency
of culture conversion associated with speciﬁc drugs.
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Study Population and Methods
We studied adults in Peru who initiated a tailored MDR-TB
regimen between 28 August 1996 and 1 April 2007. The Peru
MDR-TB treatment programme has been described else-
where, including the procedures used for identifying MDR-TB
suspects [10–12], designing MDR-TB treatment regimens [3],
delivering community-based MDR-TB treatment [4], and
performing smear, culture and susceptibility testing [13]. Drug
susceptibility testing (DST) was performed routinely at the
initiation of MDR-TB treatment. The design of tailored
treatment regimens followed international guidelines for the
management of drug-resistant TB [1,2,14]. Drugs were chosen
hierarchically from the following groups: ﬁrst-line drugs
(ethambutol or pyrazinamide), second-line injectables (kana-
mycin or capreomycin), ﬂuoroquinolones (ciproﬂoxacin or
oﬂoxacin), and oral second-line drugs [ethionamide, cycloser-
ine and para-aminosalicylic acid (PAS)]. If this did not result in a
regimen that included at least ﬁve drugs likely to be effective,
drugs of unclear efﬁcacy (e.g. clofazimine, amoxicillin-clavula-
nate) were also included. For design of salvage regimens, there
was no strict protocol, but physicians generally followed the
same principles, giving highest priority to drugs that the patient
had never received previously. Every effort was made to
include a ﬂuoroquinolone (usually moxiﬂoxacin) and an
injectable (usually capreomycin) because these drugs were
less likely to have been used in MDR-TB treatment.
According to the Peruvian national treatment protocol, all
MDR-TB patients were asked to submit sputum specimens for
culture on a monthly basis during treatment. Culture and ﬁrst-
line DST were performed at the national reference laboratory.
National protocols did not include guidelines for when to
request second-line DST in patients who were persistently
culture-positive. During the study period, second-line DST was
available, but took months because cultures had to be shipped
to a supranational reference laboratory in Massachusetts, USA.
For purposes of analysis, all DST results available up to the
start of the follow-up period were included; if a drug ever
tested resistant, it was considered resistant. All bacteriological
results were regularly collected and entered into a web-based
database that contained information about all TB drugs
received, including the dose, start date and end date for each
drug [15].
We ﬁrst identiﬁed persistently positive periods within the
series of culture results of each individual patient. These were
deﬁned as 180-day periods at any time during treatment with
at least four positive sputum cultures, separated by at least
14 days. A persistently positive date was deﬁned as the date
of the last positive culture in a persistently positive period.
Salvage therapy was deﬁned as the use of at least one new,
never-used drug added to the regimen of a patient within
30 days before or after a persistently positive date. The
following did not meet the deﬁnition of salvage therapy: (i) a
dose increase, (ii) the use of a drug previously taken by the
patient during the tailored MDR-TB regimen, or (iii) a drug
that was started within 90 days before or after resective
surgery. If several drugs had been started within 30 days of
each other, they were considered to be part of a single
salvage regimen for the purpose of analysis. For the small
number of patients who received more than one course of
salvage therapy, we used the ﬁrst one for the analysis,
assuming that subsequent salvage therapy would be much less
likely to be successful after a failed course of salvage therapy.
A switch between ethionamide and prothionamide was not
considered an addition of a new drug because there is no
evidence of difference in activity between the drugs. A switch
from an early-generation quinolone (ciproﬂoxacin, oﬂoxacin)
to a later-generation ﬂuoroquinolone (levoﬂoxacin, moxiﬂox-
acin), however, was considered an addition of a new drug
because there was a theoretical improvement in anti-TB
activity.
Culture conversion was deﬁned as three consecutive
negative culture results at least 14 days apart. Sputum samples
were collected for culture every month according to
programme guidelines, but the exact interval between cultures
could vary a few days in either direction depending on the
schedule of the patient. If a patient received resective surgery
during the 180-day follow-up period, he or she was censused
on the date of surgery. We calculated OR with chi-squared
tests (SAS, version 8.02, Cary Institute, NC, USA) to
determine the associations between speciﬁc drugs and culture
conversion among salvage patients. All reported p-values are
two-sided. This study was approved by the Harvard Medical
School Committee on Human Studies.
Results
A total of 4525 individuals initiated a tailored MDR-TB regimen
during the study period and had at least one 180-day period
that included four culture results available for analysis. Of 625
(13.8%) patients who had at least one persistently positive
episode, we identiﬁed 213 patients who received at least one
course of salvage therapy and 291 patients who never received
salvage therapy. The remaining 121 patients had a documented
change in treatment regimen, but not around the time of a
persistently positive episode (Fig. 1). Clinical characteristics
and resistance patterns of salvage and non-salvage patients are
shown in Table 1.
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Salvage therapy was initiated after a median of 11 months
(range 7–38 months) after the start of the MDR-TB treatment
regimen. Salvage regimens included a median of two new drugs
(range 1–6) and nine (range 5–13) total (new plus previously
used) drugs (Fig. 2). The most frequently used new drug was
moxiﬂoxacin, followed by capreomycin, amoxicillin-clavula-
nate, kanamycin and clarithromycin (Table 2). Eleven salvage
patients received surgery during the 180-day follow-up period;
these patients were censused at the surgery date. Nineteen
(8.9%) patients died during the follow-up period. Culture
conversion occurred in 65 (30.5%) salvage patients. After
culture conversion, however, 29 (45%) had at least one
subsequent positive culture, and 11 (16.9%) eventually died.
Salvage regimens that included moxiﬂoxacin were signiﬁ-
cantly more likely to be followed by culture conversion than
those that did not (OR 2.1; p 0.02; Table 3). This association
was signiﬁcant even in the subset of 78 patients who received a
salvage regimen that contained moxiﬂoxacin as the only new
drug. Eight of 16 patients (50%) who received a salvage
regimen with moxiﬂoxacin as the only new drug experienced
sputum conversion, compared with 13 of 62 (21%) of those
who received another new drug (OR 3.8; p 0.02).
625 patients with at least one 
persistently positive date 
4525 patients with at least 180 
days of treatment and four culture 
121 patients who had a 
change in treatment 
regimen that was not 
during a persistently 
positive period 
213 patients who 
received salvage 
therapy
291 patients who did 
not receive salvage 
therapy
FIG. 1. Cohort selection.
TABLE 1. Clinical characteristics of salvage patients and non-salvage patients
Characteristic
Salvage Non-salvage
p value
Number
(%)
Median
(IQR)
Number
(%)
Median
(IQR)
Age (years) 28 (16)
(n = 209)
29 (14)
(n = 261)
0.77
Male 128 (60%)
(n = 213)
174 (60%)
(n = 291)
0.95
Number of previous TB treatments 2 (1)
(n = 201)
2 (1)
(n = 240)
0.46
Baseline body mass index 19.2 (3.5)
(n = 124)
19.6 (4.9)
(n = 176)
0.31
Bilateral and cavitary disease on chest X-ray 80 (50%)
(n = 159)
85 (46%)
(n = 184)
0.45
Documented resistance to isoniazid and rifampicin (MDR) 183 (92%)
(n = 200)
225 (90%)
(n = 250)
0.59
MDR plus resistance to any ﬂuoroquinolone 28 (18%)
(n = 157)
48 (24%)
(n = 198)
0.14
MDR plus resistance to any second-line injectable 78 (46%)
(n = 169)
103 (49%)
(n = 210)
0.58
MDR plus resistance to any ﬂuoroquinolone or any second-line injectable (pre-XDR) 85 (50%)
(n = 170)
104 (50%)
(n = 207)
0.96
MDR plus resistance to any ﬂuoroquinolone and any second-line injectable (XDR) 19 (12%)
(n = 156)
39 (20%)
(n = 198)
0.06
IQR, interquartile range; MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant.
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FIG. 2. Number of drugs used in the salvage regimen (n = 213).
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No signiﬁcant difference was observed in culture conver-
sion by number of new drugs in the salvage regimen or by
extent of resistance (Table 3).
Discussion
For MDR-TB patients with persistently positive cultures after 6
or more months of supervised treatment with a tailored
regimen of second-line TB drugs, the decision to try a salvage
regimen may be controversial because such patients have
already received almost all drugs with known activity against
M. tuberculosis. For this cohort of patients in Peru, the decision
to attempt a salvage regimen was largely based on bacterio-
logical response to the initial MDR-TB regimen. It is in this
context that we retrospectively evaluated if salvage therapy
had been effective and, if so, which drugs were associated with
culture conversion.
The two drugsmost commonly introducedweremoxiﬂoxacin
and capreomycin. Both, however, have cross-resistance with
other more commonly used TB drugs. Moxiﬂoxacin is a later-
generation ﬂuoroquinolone that is known to have signiﬁcant
cross-resistance to early-generation ﬂuoroquinolones such as
ciproﬂoxacinoroﬂoxacin.Mutations conferring resistance toone
ﬂuoroquinolone are thought to confer some level of resistance to
all members of the class [16]. Capreomycin is an injectable
polypeptide with a structure and mode of action similar to that of
the aminoglycosides: kanamycin, amikacin and streptomycin.
Several reports have documented various levels of incomplete
cross-resistance between capreomycin and kanamycin, the most
commonly used injectables for MDR-TB treatment [17,18].
In this Peru cohort, salvage regimens often included drugs of
unclear efﬁcacy against M. tuberculosis such as amoxicillin-
clavulanic acid, clofazimine and clarithromycin. The evidence
supporting the use of these drugs in TB patients consists of
sometimes conﬂicting in vitro and animal studies [19]. Clinicians
also ‘recycled’ ﬁrst-line drugs to which the patient had not
responded previously—for example, high-dose isoniazid or
streptomycin may have been used as part of a salvage regimen
when DST indicated that the infecting strain was susceptible to
higher concentrations.
Despite the limited treatment options, almost one-third of
salvage patients experienced sputum culture conversion. In the
analysis of speciﬁc drugs, only moxiﬂoxacin was signiﬁcantly
associated with culture conversion. This was despite the fact
that all of the patients were already receiving an early-
generation ﬂuoroquinolone—usually ciproﬂoxacin (750 mg
twice daily) or oﬂoxacin (400 mg twice daily) (Table 2). One
TABLE 2. Proportion of patients receiving each tuberculosis
drug (n = 213)
Drug
Received before
starting salvage
therapy
Received as a
part of salvage therapy
Moxiﬂoxacin 9.4% (20) 50.7% (108)
Capreomycin 51.2% (109) 33.8% (72)
Amoxicillin-clavulanate 56.3% (120) 23.4% (50)
Kanamycin 53.5% (114) 20.7% (44)
Clarithromycin 5.6% (12) 20.7% (44)
PAS 89.7% (191) 9.4% (20)
Streptomycin 15.0% (32) 9.4% (20)
Pyrazinamide 43.2% (92) 8.9% (19)
Ethambutol 32.9% (70) 7.5% (16)
Clofazamine 51.6% (110) 6.6% (14)
Rifabutin 1.9% (4) 5.6% (12)
Ethionamide/prothionamide 83.6% (178) 4.7% (10)
Isoniazid 5.2% (11) 3.8% (8)
Cycloserine 96.2% (205) 2.8% (6)
Ciproﬂoxacin/oﬂoxacin 90.6% (193) 2.8% (6)
Rifampicin 5.2% (11) 2.8% (6)
Levoﬂoxacin 4.2% (9) 0.5% (1)
PAS, para-aminosalicylic acid.
TABLE 3. Characteristics associated with culture conversion
after initiation of salvage therapy*
Characteristic Conversion OR (95% CI) p value
Male 37/128 (29%) 0.8 (0.5–1.5) 0.53
Female 28/85 (33%)
Age > 28 years 30/100 (30%) 0.9 (0.5–1.7) 0.85
Age ≤ 28 years 34/109 (31%)
‘Pre-XDR’ (MDR plus
ﬂuoroquinolone or
second-line injectable
resistance)
25/85 (29%) 0.8 (0.4–1.5) 0.51
Not ‘pre-XDR’ 29/85 (34%)
XDR 3/19 (16%) 0.4 (0.1–1.4) 0.14
Non-XDR 45/137 (33%)
Two or more new
drugs in salvage regimen
44/135 (33%) 1.3 (0.7–2.4) 0.39
One new drug in salvage regimen 21/78 (27%)
Moxiﬂoxacin in salvage regimen
Yes 41/108 (38%) 2.1 (1.1–3.8) 0.02
No 24/105 (23%)
Capreomycin in salvage regimen
Yes 25/72 (35%) 1.3 (0.7–2.5) 0.34
No 40/141 (28%)
Amoxicillin-clavulanate in salvage regimen
Yes 16/50 (32%) 1.1 (0.6–2.2) 0.79
No 49/163 (30%)
Kanamycin in salvage regimen
Yes 16/44 (36%) 1.4 (0.7–2.8) 0.35
No 49/169 (29%)
Clarithromycin in salvage regimen
Yes 14/44 (32%) 1.1 (0.5–2.2) 0.83
No 51/169 (30%)
PAS included in salvage regimen
Yes 6/20 (30%) 1.0 (0.4–2.7) 0.96
No 59/193 (31%)
Streptomycin in salvage regimen
Yes 7/20 (35%) 1.3 (0.5–3.3) 0.65
No 58/193 (30%)
Pyrazinamide in salvage regimen
Yes 4/19 (21%) 0.6 (0.2–1.8) 0.35
No 61/194 (31%)
Ethambutol in salvage regimen
Yes 7/16 (44%) 1.9 (0.7–5.2) 0.24
No 58/197 (29%)
Clofazimine in salvage regimen
Yes 7/14 (50%) 2.4 (0.8–7.2) 0.11
No 58/209 (28%)
Rifabutin in salvage regimen
Yes 5/12 (42%) 1.7 (0.5–5.5) 0.39
No 60/201 (30%)
Ethionamide/prothionamide in salvage regimen
Yes 1/10 (10%) 0.2 (0.03–1.9) 0.18
No 64/203 (32%)
*Drugs used in fewer than 10 patients not included in this table.
MDR, multidrug-resistant; PAS, para-aminosalicylic acid; XDR, extensively drug-
resistant.
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possible explanation is that some resistance mutations
acquired by M. tuberculosis during treatment with ciproﬂoxacin
or oﬂoxacin might not affect the susceptibility to moxiﬂoxacin
to the same degree. A recent study of mutations in the gyrA
and gyrB regions shows that different mutations may confer
different levels of resistance, though the clinical signiﬁcance of
this is yet to be determined [20]. Another possible explanation
is that early-generation ﬂuoroquinolones were unable to
penetrate sequestered, ﬁbrotic areas of the lung, such as
ﬁbrotic lesions and destroyed tissue, where M. tuberculosis can
avoid exposure to drugs. This scenario can lead to persistent
sputum culture positivity, even in a setting of perfect
adherence. In such patients, M. tuberculosis may not acquire
ﬂuoroquinolone resistance because it is not exposed to drug
pressure. Moxiﬂoxacin has excellent penetration into bron-
chial secretions, and there is some evidence of superior
penetration compared to earlier generation ﬂuoroquinolones
[21–23].
Later-generation ﬂuoroquinolones such as levoﬂoxacin,
gatiﬂoxacin and moxiﬂoxacin have lower MICs for M. tuber-
culosis than early-generation ﬂuoroquinolones such as cipro-
ﬂoxacin or oﬂoxacin, and have been found to have superior
sterilizing ability in mouse models [16,24]. Levoﬂoxacin is the
biologically active enantiomer of oﬂoxacin; levoﬂoxacin essen-
tially contains double the active enantiomer of an equivalent
dose of oﬂoxacin. The early bactericidal activity of moxiﬂox-
acin, gatiﬂoxacin, and high-dose levoﬂoxacin appear to be
higher than that of ciproﬂoxacin and oﬂoxacin [25–27].
There have been few clinical studies comparing the
outcomes of later-generation ﬂuoroquinolones with that of
early-generation ﬂuoroquinolones in the treatment of MDR-
TB. Levoﬂoxacin-containing regimens appeared to achieve
better outcomes than oﬂoxacin-containing regimens in a
retrospective study of MDR-TB treatment in Hong Kong
[24]. Gatiﬂoxacin-containing regimens seemed to achieve
better outcomes than oﬂoxacin-containing regimens in a study
in Bangladesh [28]. And an individual patient data meta-analysis
of 9153 patients with MDR-TB showed better outcomes with
regimens that used later-generation ﬂuoroquinolones com-
pared with oﬂoxacin-containing regimens [29]. In our study, all
patients who received moxiﬂoxacin as part of salvage therapy
had previously received early-generation ﬂuoroquinolones
without achieving culture conversion.
The improvement in culture conversion achieved with
moxiﬂoxacin-containing salvage regimens raises the question
of whether later-generation ﬂuoroquinolones should be used in
the initial treatment of MDR-TB rather than being reserved for
salvage therapy. If moxiﬂoxacin had been used in the initial MDR-
TB treatment regimen, somepatientsmight have goneon to cure
without ever needing a salvage regimen. ‘Saving’ drugs for future
use is a poor clinical strategy in the treatment of MDR-TB;
rather, the most effective drugs—those offering the best chance
for cure—should be used in the initial regimen designed to treat
a patient withMDR-TB. This is particularly relevant to a drug like
moxiﬂoxacin, becauseM. tuberculosis that acquires mutations in
the gyrA or gyrB regions during failed treatment with early-
generation ﬂuoroquinolones probably has reduced susceptibility
to later-generation ﬂuoroquinolones as well.
Surgical resection, such as pneumonectomy or lobectomy,
is an important salvage intervention that was not evaluated in
this study. Sputum-negative patients may undergo resection of
residual lesions to prevent relapse, while sputum-positive
patients may undergo resection of active lesions as a rescue
strategy. Resective surgery is complicated, but has been shown
to be feasible in resource-limited settings, resulting in a higher
incidence of sustained sputum culture conversion than that of
the salvage chemotherapy found in our study [30]. For this
reason, the ideal strategy for persistently positive patients who
are surgical candidates may be to combine salvage chemo-
therapy with surgical resection.
This was a retrospective study without a strict protocol for
the initiation of salvage therapy or for monitoring of drug
resistance acquisition at regular intervals. As DST was not
regularly performed during treatment, we could not assess the
effect of changes in second-line drug resistance on the
effectiveness of salvage therapy. Salvage therapy did not
include linezolid, which has since demonstrated strong
evidence of efﬁcacy, including one clinical trial [31]. Some
drugs were used much more infrequently than others,
resulting in a smaller sample size for comparison. For these
reasons, a lack of association with conversion should not be
considered deﬁnitive evidence that a speciﬁc drug has no in vivo
activity against M. tuberculosis. There could have been unmea-
sured confounding in the initial comparison; we were not able
to perform a multivariable analysis to assess confounding. The
sample size also limits detection of effect estimates greater
than two, which were of borderline signiﬁcance. This may be
the reason for no signiﬁcant association between culture
conversion and either the number of drugs in the salvage
regimen or the extent of baseline resistance.
Despite these limitations, this study suggests that salvage
therapy based on a careful history of bacteriological response
to treatment can sometimes be effective, even in extensively
treated patients. A number of new drugs have been or are
expected to be approved for treatment of MDR-TB. Initial use,
such as in compassionate-use cohorts, will include patients in
conditions similar to those described here. Close bacteriolog-
ical monitoring will be essential, as useful information about
the best way to use new drugs may be gained from analysis of
salvage therapy cohorts.
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